Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis (TolDecCOMBINEM)

NCT04530318 PHASE2 ACTIVE_NOT_RECRUITING

The aim of this project is to assess properly the clinical efficacy of TolDec therapy by imaging, clinical and surrogate end-points related with the activity of the disease.

Details

Lead sponsor	Judit Pich
Phase	PHASE2
Status	ACTIVE_NOT_RECRUITING
Enrolment	45
Start date	Mon Jan 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Mar 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Relapsing-Remitting Multiple Sclerosis

Interventions

• Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded
• Placebo

Countries

Spain